Kyverna Therapeutics, Inc.
KYTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $415 | $515 | $501 | $563 |
| Gross Profit | -$415 | -$515 | -$501 | -$563 |
| % Margin | – | – | – | – |
| R&D Expenses | $30,042 | $35,816 | $37,433 | $32,920 |
| G&A Expenses | $0 | $8,594 | $9,975 | $0 |
| SG&A Expenses | $8,270 | $8,594 | $9,975 | $7,558 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$515 | -$501 | $0 |
| Operating Expenses | $38,312 | $43,895 | $46,907 | $40,478 |
| Operating Income | -$38,727 | -$44,410 | -$47,408 | -$41,041 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,940 | $2,329 | $2,773 | $3,552 |
| Pre-Tax Income | -$36,787 | -$42,081 | -$44,635 | -$37,489 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36,787 | -$42,081 | -$44,635 | -$37,489 |
| % Margin | – | – | – | – |
| EPS | -0.85 | -0.97 | -1.03 | -0.87 |
| % Growth | 12.4% | 5.8% | -18.4% | – |
| EPS Diluted | -0.85 | -0.97 | -1.03 | -0.87 |
| Weighted Avg Shares Out | 43,415 | 43,225 | 43,216 | 43,215 |
| Weighted Avg Shares Out Dil | 43,415 | 43,225 | 43,216 | 43,215 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,000 | $2,364 | $2,825 | $3,575 |
| Interest Expense | $7 | $14 | $25 | $27 |
| Depreciation & Amortization | $415 | $515 | $501 | $563 |
| EBITDA | -$36,365 | -$41,552 | -$44,109 | -$36,899 |
| % Margin | – | – | – | – |